OBJECTIVE: Ovarian cancer (OC) is a common tumor in women, and the development of
chemoresistance is the major obstacle to its treatment. Long non-coding RNAs (LncRNAs) …

Increasing evidence has demonstrated the involvement of dysregulated long non-coding
RNAs (lncRNAs) in chemoresistance acting as potential oncogenes or tumor suppressors in …

The aim of this study was to explore the roles of the long noncoding RNA (lncRNA) urothelial
carcinoma-associated 1 (UCA1) on cisplatin resistance in ovarian cancer and the underlying …

Background Paclitaxel (PTX) occupies a considerable status in the chemotherapies of
breast cancer (BC), but the drug resistance keeps an obstructive factor of PTX treatment …

Cisplatin resistance is still one of the main reasons for failure of clinical therapy for cervical
cancer. But the underlying molecular mechanisms involved in cisplatin resistance of cervical …

Chemotherapy is the preferred therapeutic approach for the therapy of advanced ovarian
cancer, but 5-year survival rate remains low due to the development of drug resistance …

Chemoresistance constitutes the major failing of clinical therapy for bladder cancer.
However, the molecular mechanisms involved in the chemoresistance of bladder cancer are …

Paclitaxel resistance is a critical challenge in ovarian cancer treatment. This study aimed to
identify microRNAs (miRNAs) that modulate paclitaxel resistance for use as potential …

Background Some long non-coding RNAs (lncRNAs) have been found to contribute to
cisplatin resistance. Here, we identified a novel lncRNA that was downregulated in cisplatin …

Cisplatin (DDP) resistance is a principal cause leading to poor prognosis in females
suffering from ovarian cancer (OC). Long non-coding RNA (lncRNA) has been shown to …